The importance of IgE antibody levels in anti-IgE treatment

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 61, Issue 10, 2006, Pages 1216-1219

  Johansson, S G O ^a,b   Oman H ^c   Nopp, A ^a   Pettersson, S ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c MIAB   (Sweden)

Author keywords

Anti immunoglobulin E efficacy; Omalizumab; Percentage immunoglobulin E antibodies; Total immunoglobulin E

Indexed keywords

IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB;

ADOLESCENT; ADULT; AGED; ALLERGIC ASTHMA; ANTIBODY BLOOD LEVEL; ARTICLE; CAT; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MITE; PRIORITY JOURNAL; SCHOOL CHILD;

ADULT; ALLERGENS; ANIMALS; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; CATS; HUMANS; IMMUNOGLOBULIN E; MITES;

EID: 33748289464     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2006.01172.x     Document Type: Article

References (14)

1. Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF et al. Efficacy and safety of a recombinant anti-IgE antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632-638.
2. Stanworth DR, Humphrey JH, Bennich H, Johansson SGO. Inhibition of Prausnitz-Kustner reaction by proteolytic-cleavage fragments of a human myeloma protein of immunoglobulin class E. Lancet 1968;2:17-18.
3. Holt PG, Macaubras C, Stumbles PA, Sly PD. The role of allergy in the development of asthma. Nature 1999;402(Suppl.):B12-B17.
4. Casolaro V, Spadaro G, Marone G. Human basophil releasability: VI. Changes in basophil releasability in patients with allergic rhinitis or bronchial asthma. Am Rev Respir Dis 1990;142:1108-1111.
5. Nopp A, Johansson SGO, Ankerst J, Bylin G, Cardell LO, Grönneberg R et al. Basophil allergen threshold sensitivity. A useful approach to anti-IgE treatment efficacy evaluation. Allergy 2006;61:298-302.
6. Holgate ST. Implications for clinical practice, in anti-IgE therapy. A new era in the control of severe persistent allergic asthma? European Respiratory Society Congress, Copenhagen, 19 September 2005.
7. Xolair (omalizumab), Summary of Product Characteristics: http://www. emea.eu.int/humandocs/PDFs/EPAR/Xolair/H-606-PI-en-pdf.
8. Bennich HH, Ishizaka K, Johansson SGO, Rowe DS, Stanworth DR, Terry WD. Immunoglobulin E, a new class of human immunoglobulin. Bull World Health Organ 1968;38:151-152.
9. Johansson SGO, O'B Hourihane J, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001;56:813-824.
10. Host A, Andrae S, Charkin S, Diaz-Vazquez C, Dreborg S, Eigenmann PA et al. Allergy testing in children: why, who, when and how? Allergy 2003;58:1-11.
11. Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003;19:491-498.
12. MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, Mckenzie-White J et al. Down-regulation of Fc(epsilon)RI expression in human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438-1445.
13. Simpson A, Soderstrom L, Ahlstedt S, Murray CS, Woodcock A, Custovic A. IgE antibody quantification and the probability of wheeze in preschool children. J Allergy Clin Immunol 2005;116:744-749.
14. Nopp A, Johansson SGO, Lundberg M, Öman H. Simultaneous exposure of several allergens has an additive effect on multisensitized basophils Allergy: Doi: 10.1111/j.1398-9995.2006.01211.x